JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: RV521 is an orally bioactive, highly potent small-molecule inhibitor of RSV (respiratory syncytial virus) fusion protein. It is with promising pharmaceutical properties and is currently in clinical development for the treatment of RSV disease in paedriatrics, the elderly and immune-compromised patients. RV521 targets (RSV) fusion which is a surface protein that mediates RSV binding to cellular receptors. RSV infection has been an unmet medical need and RV521 is being developed to treat RSV in patients suffering with severe disease, including neonates, the elderly, the immunocompromised and those with underlying cardiovascular or respiratory disease.
References: https://clinicaltrials.gov
Related CAS#: 1903763-83-6 (HCl)
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Recommend by mail
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!